Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) EBIT Margin (2020 - 2025)

Maxcyte (MXCT) has disclosed EBIT Margin for 6 consecutive years, with 656.3% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 99810.0% to 656.3% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 44.72% through Dec 2025, down 1861.0% year-over-year, with the annual reading at 44.72% for FY2025, 2250.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 656.3% at Maxcyte, down from 207.19% in the prior quarter.
  • The five-year high for EBIT Margin was 341.8% in Q4 2024, with the low at 656.3% in Q4 2025.
  • Average EBIT Margin over 5 years is 163.97%, with a median of 147.45% recorded in 2021.
  • The sharpest move saw EBIT Margin skyrocketed 86807bps in 2024, then crashed -99810bps in 2025.
  • Over 5 years, EBIT Margin stood at 425.03% in 2021, then soared by 93bps to 29.01% in 2022, then plummeted by -1714bps to 526.27% in 2023, then soared by 165bps to 341.8% in 2024, then plummeted by -292bps to 656.3% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 656.3%, 207.19%, and 167.24% for Q4 2025, Q3 2025, and Q2 2025 respectively.